Concentration of vitamin D metabolite – 25(OH)D3 as a predictor of breast cancer progression

D. E. Frolova, N. Lapochkina, О. Gromova, I. Torshin
{"title":"Concentration of vitamin D metabolite – 25(OH)D3 as a predictor of breast cancer progression","authors":"D. E. Frolova, N. Lapochkina, О. Gromova, I. Torshin","doi":"10.17749/2070-4909/farmakoekonomika.2022.152","DOIUrl":null,"url":null,"abstract":"Background. Prediction of breast cancer (BC) progression is important for the timely correction of patient therapy.Objective: to assess a relationship between BC progression and degree of vitamin D deficiency.Material and methods. A retrospective controlled study was performed. The results of examining 67 women aged 29–48 years with histologically verified BC and vitamin D deficiency are presented. All patients were divided into two groups: the main group – 34 women administered with vitamin D, comparison group – 33 patients not taking vitamin D.Results. It was shown that 25(OH)D3 level less than 18.9 ng/ml was significantly associated with prominent disease progression, regardless of the tumor molecular subtype. Additional criteria were developed allowing to predict BC progression.Conclusion. In order to detect secondary changes (distant metastases in ВС patients) and improve patient monitoring, it is recommended to use additional diagnostic methods and determine the intermediate metabolite of vitamin D – 25(OH)D3 in peripheral blood.","PeriodicalId":36464,"journal":{"name":"Farmakoekonomika","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmakoekonomika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Prediction of breast cancer (BC) progression is important for the timely correction of patient therapy.Objective: to assess a relationship between BC progression and degree of vitamin D deficiency.Material and methods. A retrospective controlled study was performed. The results of examining 67 women aged 29–48 years with histologically verified BC and vitamin D deficiency are presented. All patients were divided into two groups: the main group – 34 women administered with vitamin D, comparison group – 33 patients not taking vitamin D.Results. It was shown that 25(OH)D3 level less than 18.9 ng/ml was significantly associated with prominent disease progression, regardless of the tumor molecular subtype. Additional criteria were developed allowing to predict BC progression.Conclusion. In order to detect secondary changes (distant metastases in ВС patients) and improve patient monitoring, it is recommended to use additional diagnostic methods and determine the intermediate metabolite of vitamin D – 25(OH)D3 in peripheral blood.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
维生素D代谢物- 25(OH)D3的浓度作为乳腺癌进展的预测因子
背景。预测乳腺癌(BC)的进展对于及时纠正患者的治疗非常重要。目的:评估BC进展与维生素D缺乏程度的关系。材料和方法。进行回顾性对照研究。对67名年龄29-48岁组织学证实BC和维生素D缺乏症的妇女进行了检查。所有患者被分为两组:主要组- 34名服用维生素D的妇女,对照组- 33名不服用维生素D的患者。结果表明,无论肿瘤分子亚型如何,25(OH)D3水平低于18.9 ng/ml与突出的疾病进展显著相关。制定了其他标准来预测BC的进展。为了检测继发性变化(ВС患者的远处转移)并改善患者监测,建议使用其他诊断方法并测定外周血中维生素D - 25(OH)D3的中间代谢物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Farmakoekonomika
Farmakoekonomika Medicine-Health Policy
CiteScore
1.70
自引率
0.00%
发文量
43
审稿时长
8 weeks
期刊最新文献
Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia The role of ferritin in liver disease assessment An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1